Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-Q _______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. (Exact name of registrant as specified in its char ...

Revenue and Sales Performance - Total revenue for the three months ended September 30, 2025, was $384.238 million, compared to $327.252 million for the same period in 2024, representing a year-over-year increase of approximately 17.4%[35] - Aftermarket part sales for the three months ended September 30, 2025, were $24.9 million, up from $21.1 million in 2024, reflecting a growth of about 17.9%[35] - The company recognized revenue of $11.8 million for the nine months ended September 30, 2025, that was included in the contract liability balance at the beginning of the period, compared to $12.4 million for the same period in 2024[45] - For the three months ended September 30, 2025, AAON Oklahoma reported external sales of $238.7 million, while AAON Coil Products and BASX reported external sales of $70.2 million and $75.2 million, respectively[142] Financial Position and Assets - Contract assets increased to $207.739 million as of September 30, 2025, from $135.820 million at the end of 2024, indicating a significant rise of approximately 53%[44] - Total accounts receivable increased to $267,568 thousand as of September 30, 2025, up from $148,472 thousand in December 31, 2024, representing an increase of 80.3%[53] - Total inventories increased to $256,728 thousand as of September 30, 2025, compared to $192,612 thousand as of December 31, 2024, reflecting a growth of 33.3%[54] - Total property, plant, and equipment rose to $947,478 thousand as of September 30, 2025, from $819,998 thousand as of December 31, 2024, marking an increase of 15.6%[56] - Total long-lived assets increased to $608.7 million as of September 30, 2025, compared to $525.8 million as of December 31, 2024[144] Liabilities and Debt - The company’s total contract liabilities as of September 30, 2025, were $(19.974) million, compared to $(14.913) million at the end of 2024, indicating an increase in liabilities[44] - The total minimum lease obligations, net of present value of minimum lease payments, amounted to $14,902 thousand as of September 30, 2025[52] - The company entered into a Third Amendment to its Loan Agreement, including an $80 million term loan and a $200 million revolving credit facility, which was increased to $230 million in April 2025[66] - As of September 30, 2025, the total Revolver commitment was $500 million, with outstanding borrowings of $360,142,000, leaving $139,204,000 available[68] - The Company had an outstanding balance of $360.1 million on its combined Revolver and Term Loan as of September 30, 2025[208] Expenses and Costs - Costs incurred on uncompleted contracts for the nine months ended September 30, 2025, totaled $192.207 million, compared to $132.844 million for the same period in 2024, marking an increase of approximately 44.7%[45] - Depreciation expense for the three months ended September 30, 2025, was $18,419 thousand, compared to $14,636 thousand for the same period in 2024, representing a 25.5% increase[57] - The total amount paid to representatives for the three months ended September 30, 2025, was $11.1 million, compared to $10.7 million for the same period in 2024, reflecting a year-over-year increase of approximately 3.7%[43] - Accrued liabilities increased to $120,468,000 as of September 30, 2025, from $99,347,000 as of December 31, 2024, representing a growth of approximately 21.3%[65] Tax and Compliance - The effective income tax rate for the nine months ended September 30, 2025, was 16.4%, compared to 19.3% for the same period in 2024[75] - The company recorded deferred tax assets of $10.2 million (Federal) and $2.3 million (State) related to net operating loss carryforwards of approximately $48.6 million as of September 30, 2025[84] - The company recognized an increase in deferred tax liabilities of $30.9 million due to changes in tax law effective January 1, 2025[82] Shareholder and Employee Compensation - The company awarded annual merit raises resulting in a 3.3% increase in wages in March 2024 and a 4.0% increase in March 2025[29] - The total share-based compensation expense for the nine months ended September 30, 2025, was $13.4 million, compared to $12.8 million for the same period in 2024[98] - The Company matches 175.0% up to 6.0% of employee contributions in its defined contribution plan[102] - Contributions to the defined contribution plan increased to $5,975,000 for the three months ended September 30, 2025, compared to $4,570,000 for the same period in 2024, representing a 30.8% increase[103] Market and Operational Challenges - The company is facing inflationary cost pressures and supply chain disruptions due to global health issues, impacting demand for products and financial position[209] - There are concerns regarding the tightening of labor markets, affecting the ability to hire employees for continued growth[209] - The company is monitoring fluctuations in the commercial/industrial new construction market, which may influence future performance[209] - Future levels of capital expenditures and research and development are critical for the company's growth strategy[209] - The company is focused on the integration of acquired businesses to realize synergies and cost savings[209] - Legal, regulatory, and environmental compliance is essential for the company's operations and product standards[209] - The company is assessing the creditworthiness of customers and their access to capital, which could affect revenue generation[209] - Changes in interest rates and competitive factors are being closely monitored as they may impact financial results[209] - The company is addressing cybersecurity risks and potential impacts on information technology systems[209] - The timing and market acceptance of new product introductions are crucial for future revenue growth[209] Profitability and Shareholder Returns - Basic earnings per share for the nine months ended September 30, 2025, was $0.93, down from $1.77 in 2024, a decline of 47.2%[109] - The company repurchased approximately $30.0 million of shares as of September 30, 2025, with $70.0 million remaining under the current board authorization[110] - The company declared cash dividends of $0.10 per share for the periods ending March 5, 2025, May 13, 2025, and August 14, 2025, with an annualized dividend of $0.40[113] - The company reported net income of $30,782,000 for the three months ended September 30, 2025, compared to $52,625,000 in 2024, a decrease of 41.5%[109]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-38205 ____________________ ZAI LAB LIMITED (Exact Name of Registrant as Specified in its Chart ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q ____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40969 _______________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Commission file number: 001-35362 TRIPADVISOR, INC. (Exact name of registrant as specified in its charter) Nevada 80-0743202 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-32644 BK Technologies Corporation (Exact name of registrant as specified in its charter) Nevada ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-37798 Cartesian Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 26-1622110 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 7495 New Horizon Way, Frederick, MD 21703 (Address of principal executive of ...